Mezagitamab (anti-CD38) - Primary antibody, specific to CD38, >95%, high purity, Human IgG1, Antibody of CD38, Antibody of CD38

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human,Mouse,Rhesus monkey
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab175597
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175597-100μg
100μg
10
$59.90
Ab175597-1mg
1mg
4
$279.90
Ab175597-5mg
5mg
1
$739.90
Ab175597-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,189.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameMezagitamab (anti-CD38) - Primary antibody, specific to CD38, >95%, high purity, Human IgG1, Antibody of CD38
SynonymsAcute lymphoblastic leukemia cells antigen CD38 antibody | ADP ribosyl cyclase 1 antibody | ADP ribosyl cyclase antibody | ADP ribosyl cyclase/cyclic ADP-ribose hydrolase antibody | ADP-ribosyl cyclase 1 antibody | ADPRC 1 antibody | ADPRC1 antibody | cAD
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityCD38
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeBINDING AGENT
Mechanism of actionAntibody of CD38
Product Description

Mezagitamab (anti-CD38) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab (anti-CD38) depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab (anti-CD38) has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP).

Product Properties

IsotypeHuman IgG1
Light Chain Typelambda
SDS-PAGE28.1 kDa (Light Chain) & 51.6 kDa (Heavy Chain), under reducing conditions; 182.1 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
ShapeLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS2227490-52-8

Images

Mezagitamab (anti-CD38) (Ab175597) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling DPP4 with Mezagitamab (anti-CD38) (Ab175597) conjugated with biotin (right panel) compared with Human IgG (Ab170213) conjugated with biotin - Isotype Control (left panel) and detected with SA-PE (rp156150).

Mezagitamab (anti-CD38) (Ab175597) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood lymphocytes labelling DPP4 (red) with Mezagitamab (anti-CD38) (Ab175597) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.

Mezagitamab (anti-CD38) (Ab175597) - Flow Cytometry
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Mezagitamab (anti-CD38) (Ab175597). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Mezagitamab (anti-CD38) (Ab175597) - SEC
The purity of Mezagitamab (anti-CD38) (Ab175597) is more than 95% verified by HPLC.

Associated Targets(Human)

CD38 Tclin ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303100Certificate of AnalysisMar 08, 2024 Ab175597
ZJ24F0303101Certificate of AnalysisMar 08, 2024 Ab175597
ZJ24F0303102Certificate of AnalysisMar 08, 2024 Ab175597

Specifications

References

1. Roepcke S, Plock N, Yuan J, Fedyk ER, Lahu G, Zhao L, Smithson G.  (2018)  Pharmacokinetics and pharmacodynamics of the cytolytic anti-CD38 human monoclonal antibody TAK-079 in monkey - model assisted preparation for the first in human trial..  Pharmacol Res Perspect,  (3): (e00402).  [PMID:29864242] [10.1021/op500134e]
2. van de Donk NWCJ, Usmani SZ.  (2018)  CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance..  Front Immunol,  (13): (2134).  [PMID:30294326] [10.3389/fimmu.2018.02134]
3. Korver W, Carsillo M, Yuan J, Idamakanti N, Wagoner M, Shi P, Xia CQ, Smithson G, McLean L, Zalevsky J et al..  (2019)  A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys..  J Pharmacol Exp Ther,  370  (2): (182-196).  [PMID:31085699] [10.1021/op500134e]
4. de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW et al..  (2011)  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors..  J Immunol,  186  (3): (1840-8).  [PMID:21187443] [10.1021/op500134e]
5. Jackson DG, Bell JI.  (1990)  Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation..  J Immunol,  144  (7): (2811-5).  [PMID:2319135] [10.1021/op500134e]
6. Isabelle Kuhn,Esther Kellenberger,Fatouma Said-Hassane,Pascal Villa,Didier Rognan,Annelise Lobstein,Jacques Haiech,Marcel Hibert,Francis Schuber,Hélène Muller-Steffner.  (2010-10-19)  Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme..  Bioorganic & medicinal chemistry,  18  ((22)): (7900-7910).  [PMID:20951593]
7. Swarbrick JM, Graeff R, Zhang H, Thomas MP, Hao Q, Potter BV..  (2014)  Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38..  J Med Chem,  57  (20): (8517-8529).  [PMID:25226087] [10.1021/jm501037u]
8. Jacques SA, Kuhn I, Koniev O, Schuber F, Lund FE, Wagner A, Muller-Steffner H, Kellenberger E..  (2015)  Discovery of Potent Inhibitors of Schistosoma mansoni NAD⁺ Catabolizing Enzyme..  J Med Chem,  58  (8): (3582-3592).  [PMID:25803425] [10.1021/acs.jmedchem.5b00203]
9. Becherer JD, Boros EE, Carpenter TY, Cowan DJ, Deaton DN, Haffner CD, Jeune MR, Kaldor IW, Poole JC, Preugschat F, Rheault TR, Schulte CA, Shearer BG, Shearer TW, Shewchuk LM, Smalley TL, Stewart EL, Stuart JD, Ulrich JC..  (2015)  Discovery of 4-Amino-8-quinoline Carboxamides as Novel, Submicromolar Inhibitors of NAD-Hydrolyzing Enzyme CD38..  J Med Chem,  58  (17): (7021-7056).  [PMID:26267483] [10.1021/acs.jmedchem.5b00992]
10. Deaton DN, Haffner CD, Henke BR, Jeune MR, Shearer BG, Stewart EL, Stuart JD, Ulrich JC..  (2018)  2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships..  Bioorg Med Chem,  26  (8): (2107-2150).  [PMID:29576271] [10.1016/j.bmc.2018.03.021]
11. States, D J DJ, Walseth, T F TF and Lee, H C HC..  (1992)  Similarities in amino acid sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen CD38..  Trends in biochemical sciences,      [PMID:1471258]
12. Tohgo, A A and 8 more authors..  (1994)  Essential cysteine residues for cyclic ADP-ribose synthesis and hydrolysis by CD38..  The Journal of biological chemistry,    (18):   [PMID:7961800]
13. Takasawa, S S and 7 more authors..  (1993)  Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP..  The Journal of biological chemistry,    (15):   [PMID:8253715]
14. Yagui, K K and 13 more authors..  (1998)  A missense mutation in the CD38 gene, a novel factor for insulin secretion: association with Type II diabetes mellitus in Japanese subjects and evidence of abnormal function when expressed in vitro..  Diabetologia,      [PMID:9754820]
15. Hillman, R Tyler RT, Green, Richard E RE and Brenner, Steven E SE..  (2004)  An unappreciated role for RNA surveillance..  Genome biology,      [PMID:14759258]
16. Liu, Qun Q and 5 more authors..  (2005)  Crystal structure of human CD38 extracellular domain..  Structure (London, England : 1993),      [PMID:16154090]
17. Wollscheid, Bernd B and 7 more authors..  (2009)  Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins..  Nature biotechnology,      [PMID:19349973]
18. Nata, K K and 9 more authors..  (1997)  Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase): organization, nucleotide sequence and alternative splicing..  Gene,    (28):   [PMID:9074508]

Solution Calculators

Reviews

Customer Reviews